No annual revenue total was found in EXOZYMES INC.'s SEC filings.
Exozymes Inc. (EXOZ) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$6.7 million. As of Jun 30, 2026 it held $5.7 million in cash and investments and $1.1 million in total debt.
Revenue
—
Net income
$-9.16M
-56.3% vs prior year
Operating cash flow (TTM)
$-7.00M
Free cash flow (TTM)
$-7.14M
EPS
$-1.09
-22.5% vs prior year
Dividend per share
None
Shares outstanding
8.48M
+1.3% vs prior year
Net cash
$4.57M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXOZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Monrovia, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2010788
- Former names
- Invizyne Technologies Inc (until Jan 21, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$9.7M | -$5.9M |
| Net income | -$9.2M | -$5.9M |
| Diluted EPS | -$1.09 | -$0.89 |
| Operating cash flow | -$6.5M | -$8.5M |
| Free cash flow | -$6.7M | -$8.9M |
| Total assets | $6.0M | $13.0M |
| Total liabilities | $2.6M | $2.6M |
| Stockholders' equity | $3.4M | $10.4M |
| Cash and investments | $3.0M | $9.7M |
| Total debt | $1.2M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Other events
|
Sep 18, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 17, 2026 | Jun 17, 2026 |
All 128 Exozymes Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.